Wall Street brokerages forecast that CVS Health Corp (NYSE:CVS) will announce $63.03 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Twenty Four analysts have issued estimates for CVS Health’s earnings. The highest sales estimate is $63.95 billion and the lowest is $61.64 billion. CVS Health reported sales of $47.27 billion in the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The firm is scheduled to report its next earnings report on Tuesday, November 5th.

On average, analysts expect that CVS Health will report full year sales of $252.36 billion for the current financial year, with estimates ranging from $248.37 billion to $254.27 billion. For the next fiscal year, analysts anticipate that the business will report sales of $255.92 billion, with estimates ranging from $240.19 billion to $271.07 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover CVS Health.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.89 EPS for the quarter, beating the Zacks’ consensus estimate of $1.70 by $0.19. CVS Health had a net margin of 1.91% and a return on equity of 16.15%. The company had revenue of $63.43 billion for the quarter, compared to analyst estimates of $62.66 billion. During the same period in the prior year, the firm posted $1.69 EPS. The company’s quarterly revenue was up 35.2% on a year-over-year basis.

A number of analysts have commented on the stock. Standpoint Research raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 5th. Citigroup lifted their price objective on CVS Health from $68.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Morgan Stanley reissued a “buy” rating and issued a $74.00 price objective on shares of CVS Health in a research note on Sunday, August 11th. TheStreet upgraded CVS Health from a “c+” rating to a “b-” rating in a research report on Monday. Finally, Mizuho set a $71.00 target price on CVS Health and gave the company a “buy” rating in a research report on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $75.18.

Large investors have recently made changes to their positions in the business. Nordea Investment Management AB increased its stake in CVS Health by 2.8% during the 1st quarter. Nordea Investment Management AB now owns 12,426,745 shares of the pharmacy operator’s stock valued at $670,172,000 after purchasing an additional 340,315 shares in the last quarter. Haverford Trust Co. grew its holdings in shares of CVS Health by 3.0% during the second quarter. Haverford Trust Co. now owns 1,578,669 shares of the pharmacy operator’s stock valued at $86,022,000 after buying an additional 46,182 shares during the last quarter. M&R Capital Management Inc. grew its holdings in shares of CVS Health by 3.0% during the first quarter. M&R Capital Management Inc. now owns 130,126 shares of the pharmacy operator’s stock valued at $6,965,000 after buying an additional 3,794 shares during the last quarter. Mathes Company Inc. increased its position in shares of CVS Health by 61.0% during the first quarter. Mathes Company Inc. now owns 14,250 shares of the pharmacy operator’s stock worth $769,000 after acquiring an additional 5,400 shares in the last quarter. Finally, World Asset Management Inc increased its position in shares of CVS Health by 23.7% during the first quarter. World Asset Management Inc now owns 110,866 shares of the pharmacy operator’s stock worth $5,979,000 after acquiring an additional 21,261 shares in the last quarter. Institutional investors and hedge funds own 76.06% of the company’s stock.

NYSE CVS traded up $0.39 during mid-day trading on Friday, reaching $63.99. 7,119,461 shares of the stock were exchanged, compared to its average volume of 10,862,482. The stock has a market cap of $82.82 billion, a P/E ratio of 9.04, a P/E/G ratio of 1.39 and a beta of 0.85. The company has a debt-to-equity ratio of 1.39, a current ratio of 0.95 and a quick ratio of 0.64. CVS Health has a one year low of $51.72 and a one year high of $82.15. The stock has a 50 day simple moving average of $59.26 and a 200-day simple moving average of $55.85.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Story: Google Finance

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.